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Background: Docosahexaenoic acid (DHA) complexed to human serum albumin (Alb) is neuroprotective after
experimental stroke. Here we tested using lower concentrations of albumin as part of the complex to achieve
neuroprotection. We found that lower Alb concentrations extend the therapeutic window of protection beyond 5 h
after stroke onset.
Methods: Sprague–Dawley rats were received 2 h middle cerebral artery occlusion (MCAo). The behavior was
evaluated on day 1, 2, 3 and 7 after MCAo. In the dose–response study, animals were given either DHA (5mg/kg),
Alb (0.63g/kg), DHA-Alb (5mg/kg + 0.32, 0.63 or 1.25 g/kg) or saline, i.v. 3 h after onset of stroke (n=6-8 per group).
In the therapeutic window study, DHA-Alb (5mg/kg + 1.25g/kg) was administered i.v. at either 3, 4, 5, 6 or 7 h after
onset of stroke (n=7-9 per group). Alb (1.25g/kg) was given at 3 h or 5 h and saline at 3h after onset of reperfusion.
Seven days after MCAo, infarct volumes and number of GFAP, ED-1, NeuN, SMI-71 positive cells and vessels were
counted.
Results: Moderate DHA-Alb doses (0.63 and 1.25 g/kg) improved neurological scores compared to albumin-treated
rats on days 1, 2, 3 and 7. All DHA-Alb doses (0.32, 0.63 and 1.25 g/kg) markedly reduced cortical (by 65-70%),
striatal (by 52-63%) and total infarct volumes (by 60-64%) compared to native Alb group. In the therapeutic window
study DHA-Alb led to improved neurological score and significant reductions of infarct volumes (especially in the
cortical or penumbral region), even when treatment was initiated as late as 7 hours after onset of MCAo.
Conclusions: The DHA-Alb complex affords high-grade neurobehavioral neuroprotection in focal cerebral ischemia,
equaling or exceeding that afforded by native Alb or DHA, at considerably moderate doses. It has a broad
therapeutic window extending to 7 h after stroke onset. Taken together, these finding support the potential clinical
feasibility of administering DHA-Alb therapy to patients with acute ischemic stroke.
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strokeIntroduction
Stroke is a major cause of death and disability in indus-
trialized countries. Pharmacological intervention of is-
chemic damage is critically important for controlling
brain tissue deterioration. Tissue-type plasminogen acti-
vator (tPA) administered within 3 to 4.5 h of symptom* Correspondence: lbelay@lsuhsc.edu
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reproduction in any medium, provided the oronset is still the only thrombolytic agent approved for
patients with ischemic stroke. However, the narrow
therapeutic time window and the risk of intracerebral
hemorrhage after tPA treatment pose major hurdles to
its clinical use. Therefore, development of new thera-
peutic agents for stroke is essential.
Recent studies have revealed that omega-3 essential
fatty acids (found in fish oils) may be beneficial in ameli-
orating cerebral ischemic injury [1,2]. Docosahexaenoic
acid (DHA; 22:6, n-3) is an essential omega-3-fatty acid
and is vital for proper brain function. It is also necessaryd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion, and has potent anti-inflammatory effects [3]. Sev-
eral epidemiological studies indicate that consumption
of fish is associated with reduced risk of ischemic stroke
and coronary heart disease [4]. Recently, we have
showed that DHA treatment can protect brain tissue
and promote recovery in an experimental model of acute
ischemic stroke in rats [5]. In addition, DHA administra-
tion provided neurobehavioral recovery, and reduced
brain infarction and edema when administered up to 5 h
after focal cerebral ischemia in rats [6].
Lately, special attention has been paid to human
serum albumin (Alb) therapy, which has been reported
to ameliorate neuronal damage during the acute phase
of stroke [7,8]. Alb has been shown to be highly neuro-
protective in animal models of focal cerebral ischemia
[8], global ischemia [9], hemorrhagic stroke [10,11] and
traumatic brain injury [12]. With its promising neuro-
protective bioactivity, Alb can markedly improve neuro-
logical function, and reduce blood brain barrier (BBB)
permeability and infarct volumes when administered up
to 4 h after onset of stroke. The National Institutes of
Health (NIH) funded clinical trials, the ALIAS (Albumin
in Acute Stroke), based on these promising studies to
evaluate efficacy of Alb treatment in patients with acute
ischemic stroke [13,14]. However, administration of
high-dose Alb by expanding intravascular volume may
lead to pulmonary edema and congestive heart failure in
patients [15]. We suspected that if DHA were com-
plexed with Alb, it might be possible to achieve neuro-
protection at lower, more clinically achievable doses and




The present study was conducted in accordance with
the NIH guidelines for the care and use of animals in re-
search and under protocols approved by the Institutional
Animal Care and Use Committee of the Louisiana State
University Health Sciences Center, New Orleans. Male
Sprague–Dawley rats weighing 280–345 g (Charles River
Lab., Wilmington, MA) were used in all studies.
Anesthesia was induced with 3% isoflurane in a mixture
of 70% nitrous oxide and 30% oxygen. All rats were or-
ally intubated and mechanically ventilated. Body and
cranial temperature were regulated to maintain tempera-
tures at 36° to 37°C. The right femoral artery and vein
were catheterized for blood sampling for arterial gases,
pH, plasma glucose, and drug infusion.
Animal model
The right middle cerebral artery (MCA) was temporarily
occluded in rats with nylon filament, as we previouslydescribed [16]. In brief, the right common carotid artery
(CCA) bifurcation was exposed through a midline neck
incision and the occipital artery branches of the external
carotid artery (ECA) were isolated, ligated and dissected.
After isolation of the internal carotid artery (ICA), a 3–0
monofilament coated with poly-L-lysine was advanced
through the ICA to the MCA until mild resistance was
felt. The neck incision was closed with a silk suture and
the animals were then allowed to recover. After 2 h of
MCA occlusion (MCAo), rats were reanesthetized with
the same anesthetic combination and intraluminal
sutures were carefully removed. Animals survived for 7
days with free access to food and water.
Behavioral testing
Behavioral tests were performed by an observer blinded
to the treatment groups at 60 minutes during MCAo and
then on days 1, 2, 3 and 7 after MCAo. The battery con-
sisted of two tests that have been used previously [16] to
evaluate various aspects of neurologic function: 1) the
postural reflex test, to examine upper body posture while
the animal is suspended by the tail, and 2) the forelimb
placing test, to examine sensorimotor integration in fore-
limb placing responses to visual, tactile and propriocep-
tive stimuli. Neurological function was graded on a scale
of 0 (normal) to 12 (maximal injury) as previously
described [16]. Only animals with a high-grade neuro-
logical deficit (10 or greater) were used in this study.
Treatment and experimental groups
Docosahexaenoic acid (DHA) in acid form (Cayman
Chemical, Ann Arbor, MI) was physically complexed to
human albumin by incubating 20 ml of human serum al-
bumin (25%; Baxter, Westlake Village, CA) with 5 mg
DHA/g albumin (molar ratio =0.2) as previously
described [17].
Dose–response study
Animals were randomly assigned to six treatment groups:
DHA (5mg/kg), human serum albumin (Alb; 25%, 0.63g/
kg), DHA-Alb (5mg/kg + 0.32 g/kg, 5mg/kg + 0.63 g/kg or
5mg/kg + 1.25 g/kg), or sodium chloride (0.9%, 5ml/kg).
The respective agent was administered into femoral vein at
a constant rate over 3 minutes by infusion pump at 3 h
after onset of stroke (n=6-8 per group).
Therapeutic window study
In the therapeutic window study, DHA-Alb (5mg/kg +
1.25 g/kg) was administered into femoral vein at either
3, 4, 5, 6 or 7 h after onset of stroke (n=7-9 per group).
Vehicle group received Alb (25%, 1.25g/kg) at 3 or 5 h
after onset of reperfusion. The control group received
sodium chloride (0.9%, 5ml/kg) at 3 h after onset of
stroke (n=6).
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Animals were perfused with 4% paraformaldehyde on
day 7, and brains were removed and embedded in a gel-
atin matrix using MultiBrain™ Technology (NeuroSci-
ence Associates, Knoxville, TN) as previously described
[18]. Coronal sections were stained with thionine (Nissl),
digitized at nine standardized coronal levels, and the
area of infarction was measured and analyzed using
MCID™ Core imaging software (Linton, Cambridge, Uni-
ted Kingdom) as previously described [16]. An investiga-
tor blinded to the experimental groups then outlined the
zones of infarction (which were clearly demarcated) as
well as the left and right hemispheres of each section.
Infarct volume was calculated as the integrated product
of cross-sectional area and inter-section distance and
corrected for brain swelling.
Immunohistochemical procedures were performed on
the adjacent sections to identify specific vascular and
neuronal elements in the ischemic core and penumbra.
The following antibodies were used: rat BBB (SMI-71,
Sternberger Monoclonals, Inc., Baltimore, MD) as a vas-
cular marker, glial fibrillary acid protein (GFAP, Santa
Cruz, SDS Biosciences, Sweden) to label reactive astro-
cytes, and Cd68/ED-1 (Serotec, Raleigh, NC) to activate
microglia/macrophages. Numbers of GFAP, ED1 and
SMI-71 immunopositive vessels were counted in the
cortex and subcortex at the level of the central lesion
(bregma level −0.3 mm). Data were expressed as num-
bers of positive cells and vessels per high-power micro-
scopic field (magnification X 40).
Statistical analysis
Data are presented as mean values ± SEM. Repeated
measure analysis of variance (ANOVA) followed by Bon-
ferroni procedures were used for multiple comparisons.
Two-tailed Student’s t tests were used for two-group




Rectal and cranial (temporalis muscle) temperatures, ar-
terial blood gases, and plasma glucose showed no signifi-
cant differences between animals. Albumin (1.25 g/kg)
and DHA-Alb therapy (5mg/kg + 1.25 g/kg) led to the
expected moderate reduction in hematocrit compared to
the vehicle group (Table 1). There were no adverse be-
havioral side effects observed after DHA, Alb or DHA-
Alb administration in all groups.
Dose response study
Animals treated with moderate doses of DHA-Alb (0.63
and 1.25g/kg) significantly improved the neurological
score compared to Alb-treated rats on days 1, 2, 3 and 7(Figure 1A). The lowest dose of DHA-Alb (0.32g/kg)
was not different from the Alb-treated group on day 7.
In addition, DHA treatment improved behavioral score
compared to the Alb-treated rats, but only on day 2 (by
19%) and day 3 (by 26%) (Figure 1A). All doses of DHA-
Alb significantly reduced cortical and subcortical infarct
volumes in all treated groups compared to Alb-treated
rats (Figure 1B). In addition, all doses of DHA-Alb also
reduced total corrected infarct and also cortical and sub-
cortical infarct volumes as well (Figure 1B). DHA treat-
ment alone reduced infarct volumes compared to the
Alb-treated group, but less significantly than DHA-Alb
complex. Representative images of Nissl stained brain
sections from all groups are presented in Figure 2A. The
brains of saline and albumin-treated animals exhibited a
consistent pannecrotic lesion involving both cortical and
subcortical regions of the right hemisphere, character-
ized microscopically by the destruction of neuronal, glial,
and vascular elements. By contrast, infarct size was
dramatically reduced by DHA-Alb therapy (0.63 and
1.25g/kg) (Figure 2A). DHA and the lowest dose of
DHA-Alb (0.32g/kg) also reduced infarct volume, but at
a lesser rate compared to rats treated with moderate
doses of DHA-Alb. DHA-Alb treatment decreased ED-1
positive microglia cells in the penumbra, and increased
NeuN positive neurons, GFAP positive astrocytes and
SMI-71 positive vessels in the ischemic penumbra and
core (subcortex) (Figure 2B).
Therapeutic window study
Alb and DHA-Alb treatment started at 2, 3 and 4 h after
onset of stroke significantly improved neurological scores
compared to saline, but there was no significant differ-
ence between DHA-Alb and Alb groups (Figure 3A). In
rats given DHA-Alb at 5, 6 or 7 h after stroke, neurobe-
havioral improvement exceeded that of native Alb
throughout the 7-day survival period (Figure 3B). Infarct
volumes were significantly reduced by Alb, DHA and
DHA-Alb treatment (administered at 2, 3 and 4 h) com-
pared to saline treated group (Figure 3C), but there was
no significant difference between DHA-Alb and Alb
groups. When DHA-Alb treatment was initiated as late
at 5, 6 or 7 h after onset of stroke, infarct volumes, espe-
cially in the cortical area, were dramatically reduced
compared to Alb treated group even when treatment was
delayed until 7 h (Figure 3D).
Discussion
In the first part of this study we have shown that DHA-
Alb therapy substantially improves behavioral function,
markedly reduces the volume of cerebral infarction, and
promotes cell survival in animals with acute ischemic
stroke when administered promptly at moderate doses,
which are potentially amenable to clinical applications.
Table 1 Physiological variables












0.32 g/kg 0.63 g/kg 1.25 g/kg 3h 2h 3h 4h 5h 5h 6h 7h
(n=6) (n=7) (n=6) (n=7) (n=5) (n=7) (n=7) (n=8) (n=8) (n=8) (n=8) (n=7) (n=9) (n=7) (n=9) (n=8)
Before MCAo (15 min)
Rectal temperature (oC) 36.6 ± 0.1 37.3 ± 0.1 37.1 ± 0.1 36.9 ± 0.1 37.3 ± 0.2 37.1 ± 0.1 36.8 ± 0.1 36.9 ± 0.1 37.2 ± 0.1 37.0 ± 0.1 36.9 ± 0.1 36.9 ±0.1 37.0 ± 0.1 36.8 ± 0.1 37.0 ± 0.1 36.8 ± 0.1
Cranial temperature (oC) 36.6 ± 0.1 36.8 ± 0.1 36.9 ± 0.2 36.3 ± 0.1 36.8 ± 0.2 36.6 ± 0.2 36.7 ± 0.3 36.8 ± 0.2 37.1 ± 0.1 36.9 ± 0.1 36.6 ± 0.2 36.8 ± 0.1 36.5 ± 0.2 36.5 ± 0.3 36.8 ± 0.1 36.7 ± 0.2
pH 7.4 ± 0.03 7.4 ± 0.01 7.4 ± 0.01 7.4 ± 0.01 7.4 ± 0.01 7.4 ± 0.01 7.5 ± 0.01 7.4 ± 0.01 7.5 ±0.01 7.5 ± 0.00 7.5 ± 0.01 7.4 ± 0.01 7.4 ± 0.01 7.4 ± 0.01 7.5 ± 0.01 7.4 ± 0.01
PO2, mm Hg 120 ± 7 106 ± 7 115 ± 9 115 ± 7 113 ± 8 105 ± 5 102 ± 9 109 ± 6 104 ± 6 122 ± 10 96 ± 5 106 ± 7 102 ± 7 103 ± 6 108 ± 14 107 ± 10
PCO2, mm Hg 40.0 ± 2.0 39.0 ± 1.0 38.8 ± 1.0 38.3 ± 0.7 39.4 ± 0.9 40.7 ± 0.5 37.5 ± 0.9 38.9 ± 0.7 37.6 ± 1.0 38.0 ± 0.9 39.0 ± 0.7 38.7 ± 0.8 38.6 ± 0.7 39.6 ± 1.6 47.3 ± 8.4 39.4 ± 1.0
Plasma glucose, mg/dL 151 ± 14 154 ± 8 175 ± 13 181 ± 14 183 ± 18 193 ± 15 173 ± 13 132 ± 1.0 162 ± 14 161 ± 8 160 ± 7 147 ± 7 171 ± 10 156 ± 11 168 ± 11 156 ± 8
Hematocrit, % 44 ± 1.0 43 ± 0.3 44 ± 0.9 44 ± 0.8 44 ± 0.8 44 ± 0.5 42 ± 1.0 45 ± 1.2 45 ± 1.2 43 ± 0.4 45 ± 1.2 43 ± 1.0 46 ± 0.7 44 ± 0.8 45 ± 12 43 ± 1.7
Body weight (g) 334 ± 5 324 ± 8 304 ± 11 320 ± 7 309 ± 6 304 ± 7 334 ± 14 302 ± 4 327 ± 6 317 ± 9 306 ± 8 333 ± 7 335 ± 13 321 ± 11 326 ± 7 330 ± 11
During MCAo (15 min)
Rectal temperature (oC) 36.8 ± 0.1 37.2 ± 0.1 37.0 ± 0.1 37.0 ± 0.1 37.3 ± 0.1 37.1 ± 0.1 37.2 ±0.1 36.9±0.1 37.0±0.1 37.2±0.1 37.3±0.1 37.2±0.1 37.1±0.1 37.0±0.2 37.3±0.1 37.1±0.1
Cranial temperature (oC) 36.6 ± 0.1 36.3 ± 0.1 36.6 ± 0.1 36.6 ± 0.1 36.7 ± 0.2 36.6 ± 0.1 37.0 03 37.0±0.0 37.6±0.5 37.0±0.0 37.0±0.2 36.9±0.1 36.9±0.1 36.9±0.1 36.6±0.2 37±0.0
pH 7.4 ± 0.01 7.4 ± 0.01 7.4 ± 0.01 7.4 ± 0.01 7.4 ± 0.02 7.5 ± 0.01 7.4 ± 0.1 7.4±0.01 7.4±0.01 7.5±0.02 7.4±0.02 7.4±0.02 7.4±0.00 7.4±0.01 7.4±0.01 7.4±0.02
PO2, mm Hg 112±8 97 ± 5 99 ± 7 104 ± 5 108 ±7 99 ± 4 98 ± 1 98±4 103±5 105±8 96±5 107±9 113±9 101±6 102±6 97±6
PCO2, mm Hg 40.0 ± 2.0 40.0 ± 0.0 39.2 ± 0.8 40.7 ± 1.0 39.0 ± 0.9 38.4 ± 0.8 41.0 ± 1.4 39.2±0.6 39.1±0.7 39.8±1.0 40.0±1.3 39.5±0.8 39.7±0.6 39.8±0.6 39.3±0.7 40.3±1.7
Plasma glucose, mg/dL 141 ± 7 159 ± 7 176 ± 13 181 ± 14 202 ± 19 189 ± 9 160 ± 10 148±15 150±11 156±9 145±27 151±9 169±11 159±10 149±8 147±8
Hematocrit, % 44 ± 1.0 43 ± 0.4 44 ± 1.0 44 ± 0.7 43 ± 0.4 44 ± 0.5 43 ± 1.4 46±0.5 44.6±1.4 45±0.8 46±0.9 44±1.0 46±0.9 44±1.1 47±1.1 46±1.3
15 min after treatment
Rectal temperature(oC) 37.2±0.3 36.6±0.2 37.2±0.1 37.2±0.3 37.1±0.1 37.0±0.1 36.7±0.1 37.0±0.1 37.2±0.2 36.7±0.1 37.0±0.2 37.1±0.1 37.1±0.2 37.1±0.2 37.1±0.2 37.2±0.1
Cranial temperature(oC) 37.2±0.2 36.6±0.2 37.5±0.2 37.9±0.4 37.7±0.3 37.2±0.2 36.1±0.1 36.1±0.1 36.8±0.3 36.3±0.2 36.4±0.3 36.3±0.2 36.8±0.2 36.3±0.3 36.1±0.1 36.8±0.2
Hematocrit, % 45±1.1 44±0.9 37±0.3 40±0.6 37±0.5 35±0.7* 43±1.4 44±1.0 35±1.4* 35±0.8* 38±0.6* 35±0.6* 36±0.8* 36±0.8* 36±0.6* 36±1.1*
1 day after treatment
Rectal temperature (oC) 38.3±0.2 38.3±0.2 38.4±0.1 37.8±0.2 38.0±0.3 37.7±0.1 38.0±0.2 38.0±0.2 38.1±0.3 37.8±0.5 37.0±0.2 37.7±0.3 38.0±0.3 37.6±0.2 37.8±0.1 37.7±0.2
Body weight(g) 301±6 300±7 270±10 294±7 287±7 281±6 299±14 275±7 304±9 303±10 283±10 304±10 303±15 294±16 308±9 303±14
7 days after treatment
Rectal temperature (oC) 37.8±0.3 38.0±0.2 35.1±1.4 37.6±0.3 37.8±0.2 37.8±0.1 37.7±0.1 37.5±0.2 37.7±0.2 37.7±0.1 36.7±0.9 37.4±0.5 35.8±1.3 37.2±0.2 37.4±0.1 36.4±1.2
Hematocrit, % 44±1.3 40±0.8 47±0.2 41±0.7 45±0.5 43±0.8 45±1.2 41±1.1 40±1.1 42±0.9 39±0.5 39±0.3 41±0.8 39±0.8 40±0.7 39±1.0
Body weight (g) 305±16 319±17 219±12 305±19 307±12 310±7 318±18 297±16 331±14 294±25 311±20 307±21 333±24 304±24 345±7 321±21
Values are mean ± SEM.
MCAo, middle cerebral artery occlusion.
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the existence of a broad therapeutic window of neuro-
protective efficacy with moderate-dose DHA-Alb ther-
apy, such that treatment initiated even 7 hours after
stroke onset of ischemia is highly effective.
Cerebral ischemia-reperfusion results in the rapid ac-
cumulation of free fatty acids (FFA), including arachi-
donic acid (AA; 20:4 n-6) and DHA, which are released
from membrane phospholipids. Both AA and DHA are
polyunsaturated fatty acids highly enriched in phospholi-
pids from synaptic membranes, where they are reser-
voirs of potent signaling molecules and essential for
overall membrane function [1]. DHA is necessary for
ion channels, receptors, and transporters to maintain
their proper physical conformation and is involved in
memory, synaptic membrane biogenesis and function,
and neuroprotection [5,19,20]. DHA is the precursor of
neuroprotectin D1 (NPD1), which has been associated
with reduction of neuroinflammation and activation of
antiapoptotic pathways, two main mechanisms of action
implicated in ischemic stroke [5,21,22]. Our studies re-
veal an early increase in unesterified (free) DHA in brain
ischemia [19], which initiates a pathway for docosanoid
biosynthesis [21]. Since inflammation is at the root of
many chronic diseases, DHA treatment has been
demonstrated to have beneficial effects in patients with
coronary heart disease, rheumatoid arthritis, osteopor-
osis, sepsis, asthma, cancer and age-related macular de-
generation, but its potential benefit in stroke was not
known [23]. Recently, we have shown that DHA therapy
in low (3.5 or 7 mg/kg) and medium (16 or 35 mg/kg)
doses improves neurological and histological outcomes
following focal cerebral ischemia [5]. Thus, we selected a
dose in the middle of the effective dose range (5 mg/kg)
for our studies. In addition, we demonstrated that DHA
or saline administered intravenously at 3, 4 and 5 h after
the onset of stroke reduced cerebral infarction and brain
swelling, and facilitated neurobehavioral recovery even
when treatment was delayed by up to 5 h [6].
Human serum albumin has been used for many years
in the management of a diverse range of medical and
surgical issues [24]. Alb administration has multiple
effects including volume expansion, an increase in col-
loid osmotic pressure, and hemodilution. It is used in
multiple clinical settings such as hypovolemia, shock,
burns, surgery, trauma, cardiopulmonary bypass, acute
respiratory distress syndrome, hemodialysis, acute liver
failure, and ascites [25].
Preclinical studies in rodent models of ischemic stroke
have established that that administration of Alb at high
doses (25%, 2.5 g/kg, i.v.) decreases infarct volume,
reduces brain swelling [7,26] and improves local cerebral
perfusion in affected tissue [27] Moderate doses of Alb
therapy (0.63 or 1.25 g/kg) also improve neurologicalfunction and reduce infarct volume and brain swelling,
even when treatment is delayed up to 4 hours after onset
of ischemia in rats [8]. Albumin produces its neuropro-
tective effect through several mechanisms including
brain swelling amelioration [26], BBB permeability re-
duction [10], local vascular dynamic and tissue perfusion
improvement [28,29] antioxidant activity [30], antith-
rombotic effects and anti-inflammatory activity [31],
inhibiting endothelial apoptosis and maintenance of nor-
mal astrocytic function [32] and providing essential fatty
acids to the injured brain [20].
Alb is currently under clinical trials for treatment of
focal cerebral ischemia [13,14] and subarachnoid
hemorrhage [33]. Phase I and II clinical trials have
reported that higher doses of Alb correlated with better
outcomes in subjects with acute ischemic stroke [15,34],
and a Phase III trial has begun [13,14]. The only Alb-
related adverse event encountered was mild-to-moderate
pulmonary edema, which occurred in approximately
13% of patients [15]. We suspected that if DHA were
complexed with Alb, it might be possible to achieve neu-
roprotection at lower and therefore more clinically
achievable, doses and extend the therapeutic window be-
yond 5 h after stroke onset. The results of our experi-
ments show that animals treated with moderate doses of
DHA-Alb (0.63 and 1.25g/kg) significantly improved the
neurological score compared to native Alb by 21 and
26% on day 1; by 28 and 29% on day 2; by 36 and 40%
on day 3; and by 42 and 35% on day 7, respectively. All
DHA-Alb doses markedly reduced infarct volumes com-
pared to native Alb group. In the therapeutic window
study, even when treatment was initiated as late as 7 h
after onset of MCAo, DHA-Alb therapy led to signifi-
cantly improved neurological scores and significant
reductions of infarct volumes. Due to the challenges of
treating patients in the timely manner, an extension of
the therapeutic window to 7 h will offer great opportun-
ities to clinicians treating ischemic stroke victims.
Acute stroke causes an irreversibly damaged ischemic
core, and salvageable surrounding tissue called the ische-
mic penumbra [35]. The ischemic core is characterized
by severe reduction of local cerebral blood flow (below
20%), disruption of ion homeostasis, massive release of
glutamate, and activation of proteases and endonu-
cleases, which may contribute to the acute neuronal
death observed in the ischemic hemisphere [36]. The
penumbra of ischemic stroke refers to the regions of
brain tissue, surrounding the ischemic core, where blood
flow is sufficiently reduced (below 40%) to result in hyp-
oxia severe enough to arrest physiological function, but
not so complete as to cause irreversible failure of energy
metabolism and cellular necrosis [37]. The penumbra,
which accounts for almost one-half of the initial ische-
mic lesion [38], deteriorates over a few hours following
Figure 1 Dose response study: (A) Total neurological score
(normal score=0, maximal score=12) during MCAo and at various
times after treatment. Saline, DHA 5 mg/kg), Albumin (0.63 g/kg) or
DHA-Albumin (5 mg/kg + 0.32, 0.63 or 1.25 g/kg) treatment was
administered at 3 h after onset of ischemia. (B) Histopathology on day
7 of survival. All doses of DHA-Alb significantly reduced cortical,
subcortical and total (cortical and subcortical) corrected infarct volume
compared to Alb-treated rats. Data are mean ±SEM; n=5-7 per group.
*P <0.05 versus saline group; #P <0.05 versus Alb group (repeated-
measures ANOVA followed by Bonferroni tests).
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of therapeutic intervention [36,39]. Recent studies showed
that DHA treatment decreased ED-1 –positive microglia/
macrophages, increased GFAP –positive reactive astro-
cytes and NeuN positive neurons in the ischemic penum-
bra and core [11]. Our study demonstrates that DHA-Albcomplex was able to salvage the ischemic penumbra. The
effect of DHA-Alb was evident in the cortical (penumbral
region) of the infarct through a significant 79% reduction
of cortical infarct volume when administered at 5 h, 98%
reduction at 6 h, and 76% at 7 h, as compared to Alb trea-
ted rats. This effect was associated with attenuated cellular
death of both astrocytes and neurons and fewer activated
microglia, as compared to vehicle-treated rats. GFAP ex-
pression was found in the boundary zone of infarct and
was localized to the same areas where neurons are des-
tined to survive the ischemic insult (as detected by NeuN
positive cells count). These results indicate that DHA-Alb
protects not only neurons but also astrocytes, which are
critical for the maintenance and protections of neurons
via secretion of growth factors and other neurotrophic
mediators.
We have shown here that all DHA-Alb doses used in
this study were highly neuroprotective, the therapeutic
window was extended to 7 h by complexing DHA to
human Alb (1.25 g/kg), and delayed DHA-Alb treatment
(at 5-7h) was more effective than early treatment (at 2-4h)
compared to native Alb. The exact mechanisms of DHA-
Alb neuroprotection remain obscure. We can speculate
however, that complexing DHA to human Alb provides
additive neuroprotection in experimental stroke. Lipido-
mic analysis of DHA-Alb treated postischemic brains
revealed a large accumulation of NPD1 in the ipsilateral
hemisphere at 20 h of reperfusion after 2 h of MCAo in
rats [17]. NPD1 is a potent inhibitor of polymorpho-
nuclear leukocyte infiltration and pro-inflammatory gene
expression, and an overall mediator of neuroprotection
[6,21]. In contrast NPD1 levels did not change in either ip-
silateral or contralateral hemispheres in Alb treated rats
[17]. Studies shows that DHA-Alb can also prevent injury
to cultured human retinal pigment epithelial cells trig-
gered by oxidative stress, and that this effect is mediated
by NPD1 [40]. Albumin is actively involved in plasma
transport of FFA [41]. Because transient MCAo triggers a
massive loss of phospholipid-acyl groups, the systemic
supply of FFA to the brain, mainly AA and DHA, may be
essential to support the repair of neuronal membranes
[42]. The direct delivery of FFA to brain cells by Alb may
be favored by ischemia-induced disruption of the BBB
[43]. In fact, previous studies have reported that the integ-
rity of the BBB is preserved at 3–4 h after MCAo [44] but
that progressive acute disruption of the BBB occurs be-
tween 5–6 h following MCAo [43]. In addition, immuno-
histochemical analysis reveals that following MCAo,
viable-appearing cortical neurons and endothelial cells
within the ischemic zone take up Alb [45]. Thus, this may
be evidence in favor of a direct protective role of Alb, not
only as a free-radical and toxic-product scavenger [31],
but also as a supplier of DHA.
Figure 2 Histopathology: (A) Computer-generated MosaiX processed images (Zeiss Axio Imager.M1; AxioVision Release 4.6.3) of Nissl
stained paraffin-embedded brain sections from rats treated with saline, DHA (5 mg/kg), Albumin (0.63 g/kg) or DHA-Albumin (5 mg/kg +
0.32, 0.63 or 1.25 g/kg). Saline and Alb-treated rats show large cortical and subcortical infarction. Rats treated with DHA shows less extensive
damage. In contrast, DHA-Albumin treated rats show very small infarction, mostly in the subcortical area. (B) Coronal brain diagram showing locations
of regions for cell counts in cortex (A, B and C) and subcortex (S). Number of GFAP positive astrocytes, ED-1 positive microglia cells, NeuN positive
neurons and SMI-71 positive vessels were counted on day 7 after 2 h of MCAo. DHA-Alb treatment decreased ED-1, increased NeuN, GFAP positive cell
counts and SMI-71 positive vessels. Data are mean ±SEM; n=5-7 per group. *P <0.05 versus saline group; #P <0.05 versus Alb group (repeated-
measures ANOVA followed by Bonferroni tests).
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Figure 3 Therapeutic window study. Saline and DHA (5 mg/kg) were administered at 3h, Albumin (1.25 g/kg) at 3 h or 5 h and DHA-Albumin
(5 mg/kg + 1.25 g/kg) at 2, 3, 4, 5, 6 or 7 h after onset of MCAo. (A) Total neurological score in Alb, DHA and DHA-Alb (at 2, 3 and 4h) and (B)
Alb, DHA-Alb (at 5, 6 and 7 h) treated groups. Total, cortical and subcortical infarct volumes in (C) Alb, DHA and DHA-Alb (at 2, 3 and 4 h) and (D)
Alb, DHA-Alb (at 5, 6 and 7 h) treated groups. DHA-Alb therapy led to significantly improved neurological score and highly significant reductions
of total, cortical and subcortical infarct volumes, even when treatment was initiated as late as 7 h after onset of MCAo. Data are mean ±SEM;
n=7-9 per group. *P <0.05 versus saline group; #P <0.05 versus Alb group (repeated-measures ANOVA followed by Bonferroni tests).
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The current study has shown that moderate doses of
DHA-Alb complex affords high-grade neuroprotection
in focal cerebral ischemia, equaling or exceeding that
afforded by native Alb or DHA. Importantly DHA-Alb
therapy initiated as late as 7 h after onset of stroke
improved behavioral scores and reduced infarct volume.
This 7-hour time frame is clinically relevant in that it is
logistically difficult to institute therapy in many patients
with acute stroke at earlier times. We therefore suggest
that this agent offers great promise in the therapy of
cerebral ischemia and we propose that it may now be
appropriate to consider early-phase clinical trials in
patients with acute ischemic stroke.
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